Coinfection Clinical Trial
Official title:
Potential Clinical and Biological Effects of Viral and Bacterial Co-infections in Otherwise Healthy Children in Pediatric Department
Co-occurence of multiple pathogens in children is a known phenomenon, however the potential
effect on the probability to develop a disease and on its severity, as well as the
relationships between them, has not been studied adequately.
In this study, children admitted to the pediatric department with a clinical presentation of
an infectious disease were tested for the presence of multiple pathogens. Data about their
clinical status and about the accessory examinations performed during hospitalization were
collected and analyzed.
Introduction The relationship between viral and bacterial infections in the respiratory
tract in children has long been learnt and documented in the medical literature. A large
scale American study which was held during the "swine flu" (influenza A H1N1) pandemic in
2009-2010 documented pneumonia (or other pulmonary infection) of bacterial source in one
third of the patients admitted to intensive care units (PICU - Pediatric Intensive Care
Unit) [1]. Similar data and even higher incidence rates also exist for bronchiolitis caused
by RSV (respiratory syncytial virus) [2]. These and similar studies raise questions about
the real need for antibiotic treatment and whether it is being judiciously prescribed (as it
turned out, for example, that there are places in the world where 30-90% of the viral
bronchiolitis cases are treated with antibiotics [3]), which puts the patient at risk for
side effects and potentially increases bacterial resistance. Moreover, one cannot ignore the
fact that otherwise healthy children and children with comorbidity (such as chronic carrier
state or relevant background disease) are not always being addressed separately in these
studies. Despite all this, there is consensus that children with respiratory viral disease,
mainly one that requires hospitalization in PICU, will benefit from empirical antibiotic
treatment [4, 5]. On the other hand, when it comes to the potential impact of antiviral
treatment on the course of a pulmonary bacterial disease during infection with influenza
virus, the results are not encouraging, but the seasonal vaccination plays a key role in
reducing the above morbidity [6]. As to whether the presence of a viral infection at the
same time affects the severity of pulmonary bacterial infection (i.e. The disease is more
serious than that of a viral origin only), there is evidence demonstrating an increase in
mortality, duration of mechanical ventilation and duration of hospitalization in mixed
bacterial and viral disease [7]. Several studies found and isolated some viruses of
different types in the same respiratory ailment, but unanimity as to whether there is
correlation between the number of viruses and the severity of the disease is missing [8, 9].
In addition to the multiplicity of sources dealing with the link between viral and bacterial
respiratory infections, especially influenza and RSV, there is recent evidence in the
literature of a viral-bacterial etiology in acute otitis media [10, 11], but so far a
limited number of works has been made about the same relationship of other viruses or in
other systems.
The goals of this article:
1. To determine whether the data available in the context of mixed infections in
respiratory diseases (see above) are also valid for diseases in other body systems.
2. To discover whether the relationship between viral and bacterial infection is as strong
as in the respiratory system
3. to study the impact of the co‐infection on morbidity (severity, length of stay,
complications)
4. to link between specific infection and its common mixed pathogens
5. to specify age sections, gender, demographic characteristics, clinical condition, at
which co-infections (and relevant consequences) predominate
Methods The study group comprised currently or recently febrile, otherwise healthy children
aged 0 to 17 years admitted at several medical centers (Hillel Yaffe, Bnai Zion) in Israel,
who were found to have viral, bacterial or both infections. Exclusion criteria are listed
below (Table 1).
When a child meeting the above criteria was admitted, parent (or child's legal custodian)
were given verbal and written explanation by a clinical investigator, signed an informed
consent and approved him to collect blood samples and nasal or rectal swab. In accordance to
the clinical presentation, additional tests were performed and included blood, urine and
stool cultures and some viral and bacterial serologies.
For each patient, individual history was taken; presenting symptoms, physical examinations
and lab results were documented; and additional data such as antibiotic therapy, length of
stay and complications were collected during hospitalization by authorized medical staff
using standard techniques and methods.
Specimen sampling:
- Nasal swab
- Blood sampling with CBC and chemistry tubes
- Rectal swab (only in case of diarrhea)
Laboratory procedures:
Specimens were immediately placed in a refrigerator at 4°C, transferred to MeMed laboratory
no longer than 5 hours following sampling.
In the laboratory, blood tests included CBC, bacterial and viral PCR incl. ELISA.
Although clinical signs were usually documented in a great detail, this method is
problematic and prone bias for the purpose of defining infection, owing to the
investigator's individual interpretation. Thus, in this study only microbiological
definitions were used. Viral infection was defined as PCR positive for viral genome or as
the presence of IgM antibody against viral specific antigen.
Bacterial infection required PCR positive for bacterial genome sequence, or colony counts
105 cfu/ml of diagnostic sample for each single species obtained, or the presence of IgM
antibody against bacterial specific.
Data analysis:
All of the above information was transferred to and arranged in a designated database
developed and maintained by the sub-investigators.
In the database, the investigators applied the exclusion criteria, found all patients with
viral and bacterial co-infections and analyzed the investigated variants.
Table 1: Exclusion Criteria Afebrile for more than 72 hours
Chronic illness Immune compromised (due to immunosuppressive drugs, neoplastic disease,
etc.) History of prematurity or IUGR Not fully vaccinated for age according to national
routine vaccination program
Infection not being the primary diagnosis
Under antibiotic therapy:
Currently receiving Recently received (less than 48 hours) No infection was documented
during research period
;
Observational Model: Cohort, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05318235 -
Virus Interactions in the Respiratory Tract; a Cohort Study With Children
|
||
Enrolling by invitation |
NCT04984772 -
Prospective Cohort of HIV/HBV-coinfected Patients in Europe
|
||
Completed |
NCT01718301 -
HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin
|
Phase 3 | |
Recruiting |
NCT03800394 -
Pharmacokinetics of Intracellular TFV-DP and FTC-TP in HIV-infected Adolescents
|
||
Recruiting |
NCT03800407 -
Contributing Factors for Poor HIV Treatment Response in Children With TB/HIV Coinfection
|
||
Recruiting |
NCT03800381 -
Adequacy of the New Pediatric Isoniazid/Rifampin/Pyrazinamide (HRZ) Tablet
|
||
Enrolling by invitation |
NCT02699736 -
EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV
|
||
Recruiting |
NCT04410263 -
Microbiota in COVID-19 Patients for Future Therapeutic and Preventive Approaches
|